Literature DB >> 14647725

[Clinical practice parameters for hemodynamic support of pediatric and neonatal patients in septic shock].

Joseph A Carcillo1, Alan I Fields.   

Abstract

BACKGROUND: The Institute of Medicine has called for the development of clinical guidelines and practice parameters to develop "best practice" and potentially improve patient outcome.
OBJECTIVE: To provide American College of Critical Care Medicine clinical guidelines for hemodynamic support of neonates and children with septic shock.
SETTING: Individual members of the Society of Critical Care Medicine with special interest in neonatal and pediatric septic shock were identified from literature review and general solicitation at Society of Critical Care Medicine Educational and Scientific Symposia (1998-2001).
METHODS: The Medline literature database was searched with the following age specific keywords: sepsis, septicemia, septic shock, endotoxemia, persistent pulmonary hypertension, nitric oxide, and extracorporeal membrane oxygenation. More than 30 experts graded literature and drafted specific recommendations by using a modified Delphi method. More than 30 more experts then reviewed the compiled recommendations. The task force chairman modified the document until <10% of experts disagreed with the recommendations.
RESULTS: Only four randomized controlled trials in children with septic shock could be identified. None of these randomized trials led to a change in practice. Clinical practice has been based, for the most part, on physiologic experiments, case series, and cohort studies. Despite relatively low American College of Critical Care Medicine-graded evidence in the pediatric literature, outcomes in children have improved from 97% mortality in the 1960s to 60% in the 1980s and 9% mortality in 1999. U.S. hospital survival was three fold better in children compared with adults (9% vs. 27% mortality) in 1999. Shock pathophysiology and response to therapies is age specific. For example, cardiac failure is a predominant cause of death in neonates and children, but vascular failure is a predominant cause of death in adults. Inotropes, vasodilators (children), inhaled nitric oxide (neonates), and extracorporeal membrane oxygenation can be more important contributors to survival in the pediatric populations, whereas vasopressors can be more important contributors to adult survival.
CONCLUSION: American College of Critical Care Medicine adult guide lines for hemodynamic support of septic shock have little application to the management of pediatric or neonatal septic shock. Studies are required to determine whether American College of Critical Care Medicine guidelines for hemodynamic support of pediatric and neonatal septic shock will be implemented and associated with improved outcome.

Entities:  

Year:  2002        PMID: 14647725

Source DB:  PubMed          Journal:  J Pediatr (Rio J)        ISSN: 0021-7557            Impact factor:   2.197


  4 in total

1.  Singapore Paediatric Resuscitation Guidelines 2016.

Authors:  Gene Yong Kwang Ong; Irene Lai Yeen Chan; Agnes Suah Bwee Ng; Su Yah Chew; Yee Hui Mok; Yoke Hwee Chan; Jacqueline Soo May Ong; Sashikumar Ganapathy; Kee Chong Ng
Journal:  Singapore Med J       Date:  2017-07       Impact factor: 1.858

2.  Clinical effects of adding fludrocortisone to a hydrocortisone-based shock protocol in hypotensive critically ill children.

Authors:  Kiran B Hebbar; Jana A Stockwell; James D Fortenberry
Journal:  Intensive Care Med       Date:  2010-12-09       Impact factor: 17.440

Review 3.  Elucidating the role of reversible protein phosphorylation in sepsis-induced myocardial dysfunction.

Authors:  Angela Lorts; Timothy Burroughs; Thomas P Shanley
Journal:  Shock       Date:  2009-07       Impact factor: 3.454

4.  Bacterial sepsis in Brazilian children: a trend analysis from 1992 to 2006.

Authors:  Cristina Malzoni Ferreira Mangia; Niranjan Kissoon; Otavio Augusto Branchini; Maria Cristina Andrade; Benjamin Israel Kopelman; Joe Carcillo
Journal:  PLoS One       Date:  2011-06-03       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.